Sign in to view content

Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First-Time 26-Week Interim Analysis Results From the Phase 2 LUNA Study

Charles C Wykoff, MD, PhD, FASRS

Video
Published 2024

Related

Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023
Retinal Vascular Disease Symposium
Annual Meeting Talks
2020
Precision Subretinal Delivery for Cell and Gene Therapy
Allen C Ho, MD FASRS
Updates from the Field
2019

Category: AMD-Neovascular

See more